Should all BRCA1 mutation carriers with stage i breast cancer receive chemotherapy?

Breast Cancer Research and Treatment

Volumn 138, Issue 1, 2013, Pages 273-279

  Narod, Steven A ^a   Metcalfe, Kelly ^a,b   Lynch, Henry T ^c   Ghadirian, Parviz ^d   Robidoux, Andre ^d   Tung, Nadine ^e   Gaughan, Elizabeth ^e   Kim Sing, Charmaine ^f   Olopade, Olufunmilayo I ^g   Foulkes, William D ^h   Robson, Mark ⁱ   Offit, Kenneth ⁱ   Jakubowska, Ania ^j   Byrski, Tomasz ^j   Huzarski, Tomasz ^j   Sun, Ping ^a   Lubinski, Jan ^j  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f BRITISH COLUMBIA CANCER AGENCY   (Canada)

^g UNIVERSITY OF CHICAGO   (United States)

^h MCGILL UNIVERSITY   (Canada)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j POMERANIAN MEDICAL UNIVERSITY   (Poland)

more..

Author keywords

BRCA1; Breast cancer; Stage I; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; ESTROGEN RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL EVALUATION; DISEASE ASSOCIATION; DRUG EFFECT; DRUG USE; FEMALE; FOLLOW UP; GENE MUTATION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

EID: 84874665352     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2429-x     Document Type: Article

References (15)

1. Senn HJ, Thürlimann B, Goldhirsch A, Wood WC, Gelber RD, Coates AS (2003) Comments on the St. Gallen Consensus 2003 on the primary therapy of early breast cancer. Breast 12:569-582
2. Bharat A, Aft RL, Gao F, Margenthaler JA (2009) Patient and tumor characteristics associated with increased mortality in young women (< or =40 years) with breast cancer. J Surg Oncol 100:248-251
3. Narod SA, Foulkes WD (2004) BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 4:665-676
4. Foulkes WD, Metcalfe K, Hanna W, Lynch HT, Ghadirian P, Tung N et al (2003) Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma. Cancer 98:1569-1577
5. Rennert G, Bisland-Naggan S, Barnett-Griness O, Bar-Joseph N, Zhang S, Rennert HS et al (2007) Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357:115-123
6. Goodwin PJ, Phillips KA, West DW, Ennis M, Hopper JL, John EM et al (2012) Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study. J Clin Oncol 30:19-26
7. Robson ME, Chappuis PO, Satagopan J, Wong N, Boyd J, Goffin JR et al (2004) A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 6:R8-R17
8. Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, Olopade OI, Eisen A, Weber B, McLennan J, Sun P, Foulkes WD, Narod SA (2004) Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22:2328-2335
9. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M et al (2010) Pathological complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28:375-379
10. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429-4434
11. Bayraktar S, Gutierrez-Barrera AM, Liu D, Tasbas T, Akar U, Litton JK et al (2011) Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat 130:145-153
12. Lee LJ, Alexander B, Schnitt SJ, Comander A, Gallagher B, Garber JE et al (2011) Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers. Cancer 117:3093-3100
13. Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L et al (2011) Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol 29:3739-3746
14. Warner E, Hill K, Causer P, Plewes D, Jong R, Yaffe M et al (2011) Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol 29:1664-1669
15. National Cancer Comprehensive Network (2011) NCNN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network, Inc. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp. Accessed 20 Dec 2012